[go: up one dir, main page]

AR070569A2 - Compuestos de arilvinilazacicloalcano, composiciones farmaceuticas que los comprenden, un proceso para prepararlos y su uso en la fabricacion de medicamentos para el tratamiento de trastornos neurodegenerativos. - Google Patents

Compuestos de arilvinilazacicloalcano, composiciones farmaceuticas que los comprenden, un proceso para prepararlos y su uso en la fabricacion de medicamentos para el tratamiento de trastornos neurodegenerativos.

Info

Publication number
AR070569A2
AR070569A2 ARP090100388A ARP090100388A AR070569A2 AR 070569 A2 AR070569 A2 AR 070569A2 AR P090100388 A ARP090100388 A AR P090100388A AR P090100388 A ARP090100388 A AR P090100388A AR 070569 A2 AR070569 A2 AR 070569A2
Authority
AR
Argentina
Prior art keywords
alkyl
heteroaryl
aryl
nr8r9
heterocyclyl
Prior art date
Application number
ARP090100388A
Other languages
English (en)
Inventor
Arielle Genevois-Barella
Craig Miller
Gary Maurice Dull
Marc Capet
Michel Cheve
Jeffrey Daniel Schmitt
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of AR070569A2 publication Critical patent/AR070569A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se revelan compuestos vinilazacicloalcano los cuales son ligandos de diversos nAChRs. Los compuestos y sus sales farmacéuticamente aceptables pueden utilizarse para preparar composiciones farmacéuticas y/o medicamentos para prevenir o tratar trastornos asociados con la disfuncion de nAChRs, especialmente dentro del sistema nervioso central o el sistema gastrointestinal. Ejemplos de tipos de trastornos que pueden tratarse incluyen trastornos neurodegenerativos, que incluyen trastornos del sistema nervioso central tales como enfermedad de Alzheimer, trastornos cognitivos, trastornos motores tales como enfermedad de Parkinson, adiccion las drogas, trastornos de conducta y trastornos inflamatorios dentro del sistema gastrointestinal. Los compuestos también pueden servir como analgésicos en el tratamiento del dolor agudo, cronico o recurrente. Reivindicacion 1: Un compuesto vinilazacicloalcano caracterizado por la formula (1) en donde la línea ondulante representa la geometría variable (E o Z) alrededor del enlace doble; X es CR2; R1 es hidrogeno, alquilo C1-6, halogeno, -OR4, -OR4R5, o -SR4; R2 es hidrogeno, alquilo C1-6, arilo, aril-alquilo C1-6, heteroarilo, heteroaril-alquilo C1-6, heterociclilo, heterociclil-alquilo C1-6, cicloalquilo, policicloalquilo, -OR6, -NR6R7, -SR6, -SOR6 o -SO2R6; en donde los grupos alquilo C1-6, cicloalquilo, heterociclilo, heteroarilo o arilo se pueden sustituir con uno o más sustituyentes seleccionados del grupo formado por F, Cl, Br, I, -R8, -OR8, -NR8R9, -CF3, -OCF3, -CN, -NO2, -SR8, -S(O)R8, -SO2R8, -O-SO2R8, -C(=O)NR6R9, -NR8C(=O)R9, -C(=O)OR8, -OC(=O) R8, -NHSO2R8, -SO2NR8R9, -C(S)NR8R9, y -NHC(S)R8; R3 es hidrogeno o metilo; R4 y R5 son, independientemente, hidrogeno o alquilo C1-6; R6 y R7 son, independientemente, hidrogeno, alquilo C1-6, arilo, aril-alquilo C1-6, heteroarilo, heteroaril-alquilo C1-6, heterociclilo, heterociclilalquilo, cicloalquilo o policicloalquilo, en donde los grupos alquilo C1-6, cicloalquilo, heterociclilo, heteroarilo y arilo se pueden sustituir con uno o más sustituyentes seleccionados del grupo formado por F, Cl, Br, I, -R8, -NR8R9, -CF3, -CN, -NO2, -C2R8, -N3, -SO2CH3, -OR8, -SR8, -C(=O)NR8R9, -NR8C(=O)R8, -C(=O)R8, -C(=O)OR8, -(CH2)qOR8, -OC(=O) R8, -OC(=O)NR8R9, y -NR8C(=O)OR8; R8 y R9 son, independientemente, hidrogeno, alquilo C1-6, o una especie que contiene un grupo aromático; en donde la especie que contiene un grupo aromático se puede sustituir con uno o más de alquilo C1-6, halogeno o amino; o R6 y R7 juntos o R8 y R9 juntos con los átomos a los cuales están unidos forman un anillo de 3 a 10 miembros; m es 1, 2, 3 o 4; y n es 1, 2 o 3; o un isomero, mezcla, enantiomero, diastereomero, tautomero o una sal farmacéuticamente aceptable de ellos; siempre que, sin embargo, el compuesto no sea: 3-(2-(1-metilpirrolidin-3-il)vinil)piridina; 3-isopropoxi-5-(2-(1-metilpirrolidin-3-il)vinil)piridina; 3-isopropoxi-5-(2-(pirrolidin-3-il)vinil)piridina; 5-(2-(1-metilpirrolidin-3-il)vinil)-3-fenoxipiridina; o 3-etoxi-5-(2-(1-metilpirrolidin-3-il)vinil)piridina. Reivindicacion 30: Un proceso para preparar compuestos arilvinilazacicloalcano de acuerdo con las reivindicaciones 1 a 12, de la formula (1) en donde: la línea ondulante representa la geometría variable (E o Z) alrededor del enlace doble; X es CR2; R1 es hidrogeno, alquilo C1-6, halogeno, -OR4, -OR4R5, o -SR4; R2 es hidrogeno, alquilo C1-6, arilo, aril-alquilo C1-6, heteroarilo, heteroaril-alquilo C1-6, heterociclilo, heterociclil-alquilo C1-6, cicloalquilo, policicloalquilo, -OR6, -NR6R7, -SR6, -SOR6 o -SO2R6; en donde los grupos alquilo C1-6, cicloalquilo, heterociclilo, heteroarilo o arilo se pueden sustituir con uno o más sustituyentes seleccionados del grupo formado por F, Cl, Br, I, -R8, -OR8, -NR8R9, -CF3, -OCF3, -CN, -NO2, -SR8, -S(O)R8, -SO2R8, -O-SO2R8, -C(=O)NR6R9, -NR8C(=O)R9, -C(=O)OR8, -OC(=O) R8, -NHSO2R8, -SO2NR8R9, -C(S)NR8R9, y -NHC(S)R8; R3 es hidrogeno o metilo; R4 y R5 son, independientemente, hidrogeno o alquilo C1-6; R6 y R7 son, independientemente, hidrogeno, alquilo C1-6, arilo, aril-alquilo C1-6, heteroarilo, heteroaril-alquilo C1-6, heterociclilo, heterociclilalquilo, cicloalquilo o policicloalquilo, en donde los grupos alquilo C1-6, cicloalquilo, heterociclilo, heteroarilo y arilo se pueden sustituir con uno o más sustituyentes seleccionados del grupo formado por F, Cl, Br, I, -R8, -NR8R9, -CF3, -CN, -NO2, -C2R8, -N3, -SO2CH3, -OR8, -SR8, -C(=O)NR8R9, -NR8C(=O)R8, -C(=O)R8, -C(=O)OR8, -(CH2)qOR8, -OC(=O) R8, -OC(=O)NR8R9, y -NR8C(=O)OR8; R8 y R9 son, independientemente, hidrogeno, alquilo C1-6, o una especie que contiene un grupo aromático; en donde la especie que contiene un grupo aromático se puede sustituir con uno o más de alquilo C1-6, halogeno o amino; o R6 y R7 juntos o R8 y R9 juntos con los átomos a los cuales están unidos forman un anillo de 3 a 10 miembros; m es 1, 2, 3 o 4; y n es 1, 2 o 3; o un isomero, mezcla, enantiomero, diastereomero, tautomero o una sal farmacéuticamente aceptable de ellos, caracterizado porque comprende: a) hacer reaccionar un aldehído de la formula (2) en donde m es 1, 2, o 3 y n es 1, 2 o 3, con una fosforano ilida de la formula PPh3=CH2 para dar un vinilazacicloalcano de la formula (3); b) hacer reaccionar el vinilazacicloalcano con un haluro de heteroarilo de la formula (4) en donde X y R1 son lo definido anteriormente e Y es halogeno; y c) remover todos los grupos protectores remanentes.
ARP090100388A 2003-03-05 2009-02-05 Compuestos de arilvinilazacicloalcano, composiciones farmaceuticas que los comprenden, un proceso para prepararlos y su uso en la fabricacion de medicamentos para el tratamiento de trastornos neurodegenerativos. AR070569A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/379,868 US7098331B2 (en) 2003-03-05 2003-03-05 Arylvinylazacycloalkane compounds and methods of preparation and use thereof

Publications (1)

Publication Number Publication Date
AR070569A2 true AR070569A2 (es) 2010-04-21

Family

ID=32926772

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP040100690A AR043469A1 (es) 2003-03-05 2004-03-04 Compuestos arilvinilazacicloalcano y composiciones farmaceuticas que los contienen
ARP090100389A AR070570A2 (es) 2003-03-05 2009-02-05 Compuesto de arilvinilazacicloalcano, una composicion farmaceutica que lo comprende y su uso en el tratamiento de enfermedades mediadas por alfa4beta2 nachr.
ARP090100388A AR070569A2 (es) 2003-03-05 2009-02-05 Compuestos de arilvinilazacicloalcano, composiciones farmaceuticas que los comprenden, un proceso para prepararlos y su uso en la fabricacion de medicamentos para el tratamiento de trastornos neurodegenerativos.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP040100690A AR043469A1 (es) 2003-03-05 2004-03-04 Compuestos arilvinilazacicloalcano y composiciones farmaceuticas que los contienen
ARP090100389A AR070570A2 (es) 2003-03-05 2009-02-05 Compuesto de arilvinilazacicloalcano, una composicion farmaceutica que lo comprende y su uso en el tratamiento de enfermedades mediadas por alfa4beta2 nachr.

Country Status (31)

Country Link
US (8) US7098331B2 (es)
EP (3) EP2085395B1 (es)
JP (3) JP4663627B2 (es)
KR (4) KR101018083B1 (es)
CN (3) CN101550132B (es)
AR (3) AR043469A1 (es)
AT (3) ATE394394T1 (es)
AU (3) AU2004217903B2 (es)
BR (1) BRPI0409576A (es)
CA (1) CA2516514C (es)
CL (1) CL2004000452A1 (es)
CY (2) CY1110391T1 (es)
DE (2) DE602004013553D1 (es)
DK (2) DK2085395T3 (es)
EA (3) EA014714B1 (es)
ES (3) ES2309507T3 (es)
GT (1) GT200400033A (es)
IL (3) IL170155A (es)
JO (1) JO2488B1 (es)
MX (1) MXPA05009386A (es)
NO (3) NO331920B1 (es)
NZ (1) NZ541795A (es)
PA (1) PA8597201A1 (es)
PE (1) PE20040930A1 (es)
PL (5) PL215059B1 (es)
PT (2) PT2085395E (es)
SI (2) SI1601670T1 (es)
TW (3) TWI339662B (es)
UY (1) UY28218A1 (es)
WO (1) WO2004078752A1 (es)
ZA (1) ZA200506790B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098331B2 (en) * 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
FR2896800B1 (fr) 2006-01-30 2008-04-11 Servier Lab Nouveaux composes pyridinylaminoalkylene-et pyridinyloxyalkylene-cyclopropanamines polysubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
WO2008157365A2 (en) * 2007-06-15 2008-12-24 Targacept, Inc. Vinylazacycloalkanes for treating neuropathic pain
US20110098312A1 (en) * 2008-05-12 2011-04-28 Targacept ,Inc Methods for preventing the development of retinopathy by the oral administration of nnr ligands
IL266097B (en) 2008-12-01 2022-07-01 Oyster Point Pharma Inc Mono-orotate acid addition salt of r(–5–)–e(–2–)pyrrolidine––3ylvinyl)pyrimidine
TW201024283A (en) 2008-12-01 2010-07-01 Targacept Inc Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
AU2010260265A1 (en) * 2009-06-17 2011-12-22 Targacept, Inc. Reversal of L-dopa-induced dyskinesia by neuronal nicotinic receptor ligands
BR112012013765A2 (pt) 2009-12-07 2016-04-26 Targacept Inc 3,6-diazabiciclo[3.1.1] heptanos como ligantes de receptor nicotínico neuronal de acetilcolina
WO2011112428A2 (en) * 2010-03-11 2011-09-15 Targacept, Inc. Arylvinylazacycloalkane compounds for constipation
US20110274628A1 (en) * 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US20140081714A1 (en) * 2012-09-19 2014-03-20 Salesforce.Com, Inc. Systems and methods of rewarding users in an on-demand system
US20140278929A1 (en) * 2013-03-15 2014-09-18 Yahoo! Inc. System and method identifying opportunities for advertising entities based on user goal achievement
MX385698B (es) * 2016-04-07 2025-03-18 Oyster Point Pharma Inc Uso de un compuesto que comprende un grupo pirrolidinilo y pirimidinilo para tratar enfermedades oculares
KR101848601B1 (ko) * 2016-07-27 2018-04-12 송기봉 일회용 위생 티슈
WO2020014217A1 (en) 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
EP3820443A1 (en) 2018-07-10 2021-05-19 Oyster Point Pharma, Inc. Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions
ES3039903T3 (en) 2020-04-28 2025-10-27 Oyster Point Pharma Inc Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000158A1 (en) 1987-07-02 1989-01-12 Pfizer Inc. Bridged-diazabicycloalkyl quinolone carboxylic acids and esters
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
US5187166A (en) 1990-07-31 1993-02-16 Nisshin Flour Milling Co., Ltd. Azabicyclo derivatives and their use as antiemetics
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
IT1274018B (it) 1994-02-23 1997-07-14 Riace Ets Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6437138B1 (en) 1996-06-06 2002-08-20 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
HU226859B1 (en) 1997-10-27 2009-12-28 Neurosearch As Phenyl- or heteroaryl-homopiperazines, their use and medicaments containing them
CA2376061A1 (en) 1999-06-07 2000-12-14 Targacept, Inc. Pharmaceutical compositions and methods for use
JP2003529547A (ja) 1999-09-14 2003-10-07 アボット・ラボラトリーズ 化学シナプス伝達のコントロールに有効な３−ピロリジニルオキシ−３’−ピリジルエーテル化合物
AU780492B2 (en) 1999-11-01 2005-03-24 Targacept, Inc. Aryl olefinic azacyclic, and aryl acetylenic azacyclic compounds, pharmaceutical compositions containing them and their use as inhibitors of nicotinic cholinergic receptors
US6624167B1 (en) * 2000-08-04 2003-09-23 Targacept, Inc. Pharmaceutical compositions and methods for use
WO2003008559A2 (en) 2001-07-19 2003-01-30 Medical College Of Georgia Research Institute Novel analogs of choline for neuroprotection and cognitive enhancement in neurodegenerative disorders
US7098331B2 (en) 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof

Also Published As

Publication number Publication date
JO2488B1 (en) 2009-10-05
PL2085395T3 (pl) 2011-05-31
US20140107164A1 (en) 2014-04-17
CA2516514C (en) 2012-02-07
EP1947100A1 (en) 2008-07-23
US8067443B2 (en) 2011-11-29
NZ541795A (en) 2008-03-28
US8633222B2 (en) 2014-01-21
TW200927745A (en) 2009-07-01
AR070570A2 (es) 2010-04-21
KR100953150B1 (ko) 2010-04-19
ES2389106T3 (es) 2012-10-23
KR20090021227A (ko) 2009-02-27
CN100526308C (zh) 2009-08-12
NO331920B1 (no) 2012-04-30
EP1601670A1 (en) 2005-12-07
JP4663627B2 (ja) 2011-04-06
US20060094732A1 (en) 2006-05-04
NO20092231L (no) 2005-10-03
CN1756754A (zh) 2006-04-05
AU2004217903A1 (en) 2004-09-16
JP2010001296A (ja) 2010-01-07
PT2085395E (pt) 2011-04-20
CY1110391T1 (el) 2015-04-29
US20040176348A1 (en) 2004-09-09
DE602004031165D1 (de) 2011-03-03
ZA200506790B (en) 2006-05-31
UY28218A1 (es) 2005-06-30
AU2004217903B2 (en) 2010-03-04
US7714001B2 (en) 2010-05-11
SI2085395T1 (sl) 2011-05-31
NO20091888L (no) 2005-10-03
JP5537084B2 (ja) 2014-07-02
DE602004013553D1 (de) 2008-06-19
NO332293B1 (no) 2012-08-20
EP2085395A1 (en) 2009-08-05
AU2008258188A1 (en) 2009-01-15
TW200927746A (en) 2009-07-01
PL216979B1 (pl) 2014-06-30
EA019240B1 (ru) 2014-02-28
PA8597201A1 (es) 2004-09-28
HK1084949A1 (en) 2006-08-11
ES2309507T3 (es) 2008-12-16
JP2006519868A (ja) 2006-08-31
NO20054120L (no) 2005-10-03
US7098331B2 (en) 2006-08-29
PL215059B1 (pl) 2013-10-31
KR20090021228A (ko) 2009-02-27
JP5537085B2 (ja) 2014-07-02
EA014714B1 (ru) 2011-02-28
DK1601670T3 (da) 2008-08-25
EP1601670B1 (en) 2008-05-07
AR043469A1 (es) 2005-07-27
PL1601670T3 (pl) 2008-10-31
US20150164894A1 (en) 2015-06-18
EP1947100B1 (en) 2011-07-27
CN101550132B (zh) 2012-03-28
PE20040930A1 (es) 2005-02-18
EA200900706A1 (ru) 2009-10-30
EP2085395B1 (en) 2011-01-19
WO2004078752A1 (en) 2004-09-16
SI1601670T1 (sl) 2008-10-31
TWI377204B (en) 2012-11-21
JP2009292825A (ja) 2009-12-17
US20100267776A1 (en) 2010-10-21
DK2085395T3 (da) 2011-04-18
EA200801764A1 (ru) 2008-12-30
KR101018083B1 (ko) 2011-03-02
PL378415A1 (pl) 2006-04-03
PL394600A1 (pl) 2011-07-18
PT1601670E (pt) 2008-07-11
CL2004000452A1 (es) 2005-05-20
AU2008258188B2 (en) 2011-02-24
ATE394394T1 (de) 2008-05-15
CA2516514A1 (en) 2004-09-16
ATE496046T1 (de) 2011-02-15
AU2008258187A1 (en) 2009-01-15
CY1111615T1 (el) 2015-10-07
ES2385941T3 (es) 2012-08-03
TWI339662B (en) 2011-04-01
CN101550132A (zh) 2009-10-07
HK1130254A1 (en) 2009-12-24
US20080293778A1 (en) 2008-11-27
TW200505909A (en) 2005-02-16
NO20054120D0 (no) 2005-09-05
EA200501425A1 (ru) 2006-02-24
KR20120014236A (ko) 2012-02-16
IL170155A (en) 2013-08-29
KR20060006006A (ko) 2006-01-18
EA010870B1 (ru) 2008-12-30
US20110152293A1 (en) 2011-06-23
US20100010042A1 (en) 2010-01-14
CN101255155A (zh) 2008-09-03
KR101185541B1 (ko) 2012-09-24
MXPA05009386A (es) 2005-11-04
ATE517893T1 (de) 2011-08-15
IL197890A (en) 2013-11-28
US8063068B2 (en) 2011-11-22
AU2008258187B2 (en) 2010-08-05
PL394604A1 (pl) 2011-07-18
BRPI0409576A (pt) 2006-04-18
HK1116800A1 (en) 2009-01-02
IL197889A (en) 2013-03-24
GT200400033A (es) 2005-05-29

Similar Documents

Publication Publication Date Title
AR070569A2 (es) Compuestos de arilvinilazacicloalcano, composiciones farmaceuticas que los comprenden, un proceso para prepararlos y su uso en la fabricacion de medicamentos para el tratamiento de trastornos neurodegenerativos.
JP6163205B2 (ja) 補体経路モジュレーターおよびその使用
JP6629947B2 (ja) 高インスリン血症に関連した症状の処置
AR107928A1 (es) Moduladores alostéricos de receptores de acetilcolina nicotínicos
ES2815373T3 (es) Procedimiento de compuesto antifúngico
AR090203A1 (es) Compuestos heterobiciclicos como inhibidores de pde10
AR115993A2 (es) Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr)
AR108184A1 (es) Proceso para preparar compuestos de isoxazolina
JP2019516766A5 (es)
MX2019004113A (es) Compuestos farmaceuticos.
JP2019511460A5 (es)
EA202090987A1 (ru) Новые пролекарства на основе катехоламина для применения в лечении болезни паркинсона
PH12018500106A1 (en) Ethynyl derivatives as metabotropic glutamate receptor modulators
JP2020536863A5 (es)
CN107001260A (zh) 3‑氧基‑3‑(芳氨基)丙酸酯、其制备方法、以及其在制备吡咯烷酮中的用途
HRP20110804T1 (hr) Benzocikloheptapiridini kao inhibitori receptora tirozin kinaze met
RU2017115305A (ru) Ингибиторы биосинтеза гепарансульфата для лечения заболеваний
JP2016525529A5 (es)
AR044134A1 (es) Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
CN111511745A (zh) 吡唑并[1,5-a][1,3,5]三嗪-2-胺类衍生物、其制备方法及其在医药上的应用
AR121299A1 (es) Inhibidores heterocíclicos de pad4
PE20200756A1 (es) Compuestos de indazol como potenciadores alostericos mglur4, composiciones y metodos de tratamiento de la disfuncion neurologica
JP2018531993A5 (es)
JP2017525717A5 (es)
PE20201151A1 (es) Moduladores alostericos positivos del receptor de dopamina d1

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FC Refusal